Edition:
United States

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

9,990JPY
17 Aug 2017
Change (% chg)

¥-130 (-1.28%)
Prev Close
¥10,120
Open
¥10,050
Day's High
¥10,200
Day's Low
¥9,990
Volume
275,500
Avg. Vol
399,554
52-wk High
¥18,820
52-wk Low
¥9,920

Latest Key Developments (Source: Significant Developments)

Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln
Friday, 4 Aug 2017 02:41am EDT 

Aug 4 (Reuters) - Sosei Group Corp <4565.T>:* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa.* Says it will complete the transaction on Aug. 10 .  Full Article

Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream
Thursday, 29 Jun 2017 03:17am EDT 

June 29(Reuters) - Sosei Group Corp <4565.T>:Says its unit Heptares Therapeutics and PeptiDream Inc <<<4587.T>>>, a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases.  Full Article

Sosei Group unit Heptares to receive $5 million milestone
Thursday, 18 May 2017 03:49am EDT 

May 18(Reuters) - Sosei Group Corp <4565.T>:Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist, discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd <<>> has triggered a $5 million payment from Teva to Heptares under the terms of their licensing and drug-discovery agreement signed in 2015.  Full Article

Sosei Group unit signs investment agreement with MiNA
Tuesday, 2 May 2017 09:54pm EDT 

May 3 (Reuters) - Sosei Group Corp <4565.T> ::* Says co's wholly owned subsidiary Sosei R&D Limited signs an investment agreement with MiNA (Holdings) Limited, which is the holding company of UK-based bio-medical firm MiNA Therapeutics Limited.* According to the agreement, the company will pay 35 million pounds for a 25.6 percent voting power and 140 million pounds for the options for potentially 100 percent stake of MiNA .  Full Article

Sosei Group unit Heptares receives $12 mln milestone payment
Wednesday, 5 Apr 2017 02:19am EDT 

Sosei Group Corp <4565.T> :Says unit Heptares received milestone payment of $12 million from AstraZeneca, on small molecule A2A antagonist AZD4635 (HTL-1071).  Full Article

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

Sosei Group appoints Andrew Oakley as CFO
Thursday, 19 Jan 2017 01:51am EST 

Sosei Group Corp <4565.T>: Says it appoints Andrew Oakley as new CFO .Says effective date will be Feb. 1.  Full Article

Sosei Group says completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis
Monday, 29 Aug 2016 02:47am EDT 

Sosei Group <4565.T>: Says its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole 50 mg, muco-adhesive tablet) for the treatment of oropharyngeal candidiasis; meeting the primary endpoint as requested for submission . Says the study was an open-label, randomized, multi-site, parallel-group, comparative clinical study to investigate the efficacy and safety of SO-1105 in comparison with a commercialized formulation of miconazole in patients with oropharyngeal candidiasis in Japan .Says the cure rate after the completion of the targeted study medication period with SO-1105 was the same as the comparator in terms of the primary endpoint.  Full Article

Sosei Group says $10 million milestone payment from Astrazeneca to Heptares
Wednesday, 6 Jul 2016 02:00am EDT 

Sosei Group Corp <4565.T>:Says Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca.  Full Article

Sosei Group says appoints Peter Bains as CEO
Friday, 24 Jun 2016 06:14am EDT 

Sosei Group : Shinichi tamura, sosei founder and group chairman, president, ceo, appointed as representative executive officer and executive chairman .Sosei appoints Peter Bains as CEO.  Full Article

BRIEF-Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln

* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa Laboratories, Inc, for $3.5 million